tirzepatide use in pregnancy Why should be avoided while taking tirzepatide? Tirzepatide and Pregnancy: Safety, Risks,

503A pharmacies are primarily regulated by state pharmacy boards rather than directly by the FDA, though the FDA retains authority to inspect and take enforcement action when concerns arise

Patients with a personal or family history of medullary thyroid cancer or MEN 2 should not take either medication

A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15 mg once weekly based on AUC) administered by subcutaneous injection twice weekly

2022 Nov;61:90-97

If you've already lost 1525% of body weight, your body has achieved a substantial metabolic reset